Visionary Health Architects and Leaders: The Strategic Role of Medical Advisors in Modern Pharma.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Pharmaceutical Medicine Pub Date : 2025-03-01 Epub Date: 2025-03-15 DOI:10.1007/s40290-025-00557-y
Selene García-García, Joan Rius-Tarruella
{"title":"Visionary Health Architects and Leaders: The Strategic Role of Medical Advisors in Modern Pharma.","authors":"Selene García-García, Joan Rius-Tarruella","doi":"10.1007/s40290-025-00557-y","DOIUrl":null,"url":null,"abstract":"<p><p>This paper reviews the pivotal role of the Medical Advisor (MA) within the medical department of the pharmaceutical industry, highlighting their essential contribution to the development, commercialization, and appropriate use of medicines. In an environment characterised by stringent regulations and increasing demands for transparency, the MA role has become an indispensable position for ensuring optimal integration between scientific innovation and commercial strategy. The work of MAs facilitates cross-functional collaboration between a board spectrum of internal teams and external stakeholders, ensuring that scientific and clinical knowledge is effectively integrated at every stage of the product lifecycle. This includes leveraging emerging new technologies such as artificial intelligence and digital health solutions, as well as using machine learning to enhance predictive analytics. Such integration is critical to addressing unmet medical needs while aligning these initiatives with broader business objectives to drive innovation, market competitiveness, and patient outcomes. We explore the key responsibilities of today's MAs, which include contributing to the generation of data through clinical trials and post-authorization studies, providing continuing medical education, and communicating accurate information to diverse audiences, including healthcare providers, regulators, and patients. Furthermore, MAs promote innovation and therapeutic progress, acting as guardians of medical ethics. This review aims to provide a comprehensive understanding of the strategic role of MAs in bridging the gap between scientific research and clinical practice. Their contributions are critical to addressing current industry challenges, ensuring that companies remain competitive and making a significant contribution to patient wellbeing and medical progress.</p>","PeriodicalId":19778,"journal":{"name":"Pharmaceutical Medicine","volume":" ","pages":"87-95"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40290-025-00557-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This paper reviews the pivotal role of the Medical Advisor (MA) within the medical department of the pharmaceutical industry, highlighting their essential contribution to the development, commercialization, and appropriate use of medicines. In an environment characterised by stringent regulations and increasing demands for transparency, the MA role has become an indispensable position for ensuring optimal integration between scientific innovation and commercial strategy. The work of MAs facilitates cross-functional collaboration between a board spectrum of internal teams and external stakeholders, ensuring that scientific and clinical knowledge is effectively integrated at every stage of the product lifecycle. This includes leveraging emerging new technologies such as artificial intelligence and digital health solutions, as well as using machine learning to enhance predictive analytics. Such integration is critical to addressing unmet medical needs while aligning these initiatives with broader business objectives to drive innovation, market competitiveness, and patient outcomes. We explore the key responsibilities of today's MAs, which include contributing to the generation of data through clinical trials and post-authorization studies, providing continuing medical education, and communicating accurate information to diverse audiences, including healthcare providers, regulators, and patients. Furthermore, MAs promote innovation and therapeutic progress, acting as guardians of medical ethics. This review aims to provide a comprehensive understanding of the strategic role of MAs in bridging the gap between scientific research and clinical practice. Their contributions are critical to addressing current industry challenges, ensuring that companies remain competitive and making a significant contribution to patient wellbeing and medical progress.

本文回顾了医药行业医疗部门中医疗顾问(MA)的关键作用,强调了他们对药品开发、商业化和合理使用的重要贡献。在监管严格、透明度要求不断提高的环境下,医学顾问已成为确保科学创新与商业战略最佳结合的不可或缺的职位。MA 的工作有助于内部团队和外部利益相关者之间的跨职能合作,确保科学和临床知识在产品生命周期的各个阶段得到有效整合。这包括利用人工智能和数字健康解决方案等新兴技术,以及使用机器学习来增强预测分析能力。这种整合对于满足未满足的医疗需求至关重要,同时还能使这些举措与更广泛的业务目标保持一致,从而推动创新、提高市场竞争力并改善患者的治疗效果。我们探讨了当今医疗服务提供者的主要职责,其中包括通过临床试验和授权后研究帮助生成数据、提供继续医学教育以及向医疗服务提供者、监管机构和患者等不同受众传达准确信息。此外,医疗管理者还促进创新和治疗进步,是医学伦理的守护者。本综述旨在全面介绍 MA 在弥合科学研究与临床实践之间的差距方面所发挥的战略作用。他们的贡献对于应对当前的行业挑战、确保公司保持竞争力以及为患者福祉和医学进步做出重大贡献至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Medicine
Pharmaceutical Medicine PHARMACOLOGY & PHARMACY-
CiteScore
5.10
自引率
4.00%
发文量
36
期刊介绍: Pharmaceutical Medicine is a specialist discipline concerned with medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution and pricing of medicines, drug-device and drug-diagnostic combinations. The Journal disseminates information to support the community of professionals working in these highly inter-related functions. Key areas include translational medicine, clinical trial design, pharmacovigilance, clinical toxicology, drug regulation, clinical pharmacology, biostatistics and pharmacoeconomics. The Journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on topical issues.Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by PRISMA statement.Original research articles reporting the results of well-designed studies with a strong link to wider areas of clinical research.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pharmaceutical Medicine may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信